Concept
Anatomie des insectes
Personnes associées (12)
Dario Floreano
Prof. Dario Floreano is director of the Laboratory of Intelligent Systems at the Swiss Federal Institute of Technology Lausanne (EPFL). Since 2010, he is the founding director of the Swiss National Center of Competence in Robotics, a research program that brings together more than 20 labs across Switzerland. Prof. Floreano holds an M.A. in Vision, an M.S. in Neural Computation, and a PhD in Robotics. He has held research positions at Sony Computer Science Laboratory, at Caltech/JPL, and at Harvard University. His main research interests are Robotics and A.I. at the convergence of biology and engineering. Prof. Floreano made pioneering contributions to the fields of evolutionary robotics, aerial robotics, and soft robotics. He served in numerous advisory boards and committees, including the Future and Emerging Technologies division of the European Commission, the World Economic Forum Agenda Council, the International Society of Artificial Life, the International Neural Network Society, and in the editorial committee of several scientific journals. In addition, he helped spinning off two drone companies (senseFly.com and Flyability.com) and a non-for-profit portal on robotics and A.I. (RoboHub.org). Books
Manuale sulle Reti Neurali, il Mulino (in Italian), 1996 (first edition), 2006 (second edition)Evolutionary Robotics, MIT Press, 2000
Bio-Inspired Artificial Intelligence, MIT Press, 2008
Flying Insects and Robots, Springer Verlag, 2010
Florian Maria Wurm
Florian Wurm received his academic training as a Biologist and Molecular Geneticist at the University of Giessen. He joined the Hoechst AG (Behringwerke) in Marburg as head of a laboratory in Virology. Working with immortalized mammalian cells for the establishment of production processes for alpha-interferons provided the first opportunity to combine basic research with medical application. In 1984 he joined Harvard Medical School in Boston as a Research Fellow in Molecular Biology. 1986 he took an offer from Genentech Inc. in San Francisco to work in Process Sciences on the development of large scale manufacturing processes for recombinant proteins. There he has held a number of leading positions and has acquired intimate knowledge in the generation of protein pharmaceuticals in mammalian cells in bioreactors (a number of which are now marketed products). In 1995 he joined the EPFL as a Professor for Biotechnology. Wurm has published more than 250 scientific papers and holds more than 20 patents/patent-applications. His H-index stands at 60 in 2021. He was Chairman (2005-2009) and is member of the Executive Board of the European Society of Animal Cell Technology (ESACT). He serves as a consultant to the pharmaceutical Biotech Industry, mainly in the fields of animal cell technology for recombinant protein production and in regulatory affairs. He works as a scientific reviewer and editior/asscciate editor for a number of international journals in the Biotech field. F.M. Wurm teaches classes to pre- and postgraduate students in the fields of Molecular and Cellular Biotechnology.
He was founder and Chief Scientific Officer of ExcellGene SA, a 2001 established company in Monthey, Switzerland. He took the position of President and CEO of ExcellGene in 2015. He retired from the CEO position in 2017 and continues to be President and Chief Scientific Officer of ExcellGene.
In 2008 Dr. Wurm was appointed Visiting Professor for Biotechnology at Jinan University in Guangzhou, China. He retired from his position at the EPFL in 2015. His laboratory is closed. With his team at ExcellGene and in collaboration with Dr. Paco Pino, Director of R&D, he continues to explore manufacturing sciences with animal cells in bioreactors.
Lucia Baldi Unser
01/2021 - present Deputy to the Associate VP for Research / Deputy to the Associate VP for Centers & Platforms, EPFL06/2017 - 12/2020 Deputy to the Dean, School of Basic Sciences, EPFL 01/2015 - 11/2017 Lecturer/Communication and outreach manager at the School of Life Sciences, EPFL04/1998 - 03/2015: Research and Teaching Associate/Lecturer, Laboratory of Cellular Biotechnology, School of Life Sciences 01/1994 - 07/1997: Visiting Fellow, Laboratory of Immunoregulation, NIAID, NIH, Bethesda, Maryland, USA1991 - 1994: Research Fellow, Laboratory of Pediatric Oncology, G. Gaslini Scientific Institute, Genova, Italy1987 - 1990: Research Fellow, Clinical Immunology and Immunogenetics Dept., Nat. Inst. for Cancer Research, Genova, Italy
Gerardo Turcatti
Senior scientific level (R&D) with extensive experience in the management of multidisciplinary technological projects. Prof. Gerardo Turcatti, directs the academic technological platform, Biomolecular Screening Facility (BSF) at the EPFL he created in 2006. In the framework of the NCCR-Chemical Biology, he is project leader of the program ACCESS (An Academic Chemical Screening Platform for Switzerland). Previously he co-founded and acted as CTO of Manteia S.A., a Swiss-based company that developed high throughput DNA sequencing technologies currently owned by Illumina and used in the ‘Next Generation Sequencing’ instruments. Prior to this experience, Prof. Turcatti had a long multidisciplinary career in R&D divisions of Biotechnology and Pharmaceutical companies with extensive expertise in several Chemical Biology-related disciplines such as Drug Screening, Chemical Biology, Bio-analytical Chemistry, DNA and Protein Chemistry. Prof. Turcatti earned his Master in Chemical Engineering at the University of Geneva and his PhD in Chemistry and Biochemistry from the EPFL where he received the award for the best doctoral thesis of the year.
Stewart Cole
Professor Stewart Cole is an international authority in bacterial molecular-genetics and genomics. He has made outstanding contributions in several fields including: bacterial anaerobic electron transport; genome analysis of retroviruses and papillomaviruses; antibiotic resistance mechanisms; and the molecular microbiology of toxigenic clostridia. His studies on isoniazid and multidrug resistance in Mycobacterium tuberculosis, together with his pioneering work on the pathogenicity, evolution and genomics of the tubercle and leprosy bacilli, have made him an undisputed leader in the field of mycobacterial research. The findings of his research are of direct relevance to public health and disease-control in both the developing world and the industrialised nations. He has published over 250 scientific papers and review articles, and holds many patents.